Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period

AIDS

Volumn 22, Issue 17, 2008, Pages 2341-2346

  Brown, Elizabeth ^a   Chi, Benjamin H ^b   Read, Jennifer S ^c   Taha, Taha E ^d   Sharma, Usha ^e   Hoffman, Irving F ^f   Pikora, Cheryl ^g   Goldenberg, Robert ^h   Fiscus, Susan A ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g Kendle International Inc   (United States)

^h DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breastfeeding; HIV infant diagnosis; Late postnatal transmission

Indexed keywords

NEVIRAPINE;

ARTICLE; BREAST FEEDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MAJOR CLINICAL STUDY; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; VIRUS TRANSMISSION; WEANING;

AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; BREAST FEEDING; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; NEVIRAPINE; POSTNATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; TIME FACTORS; VIRAL LOAD; WEANING;

EID: 56549121562     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328317cc15     Document Type: Article

References (26)

1. Benjamin DK, Miller WC, Fiscus SA, Benjamin DK, Morse M, Valentine M, McKinney RE. Rational testing of the HIV exposed infant. Pediatrics 2001; 108:1-5.
2. Dunn DT, Brandt CD, Krivine A, Cassol SA, Roques P, Borkowsky W, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995; 10:1181-1223.
3. Dunn DT, Simonds RJ, Bulterys M, Kalish LA, Moye J, de Maria A, et al. Interventions to prevent vertical transmission of HIV-1: effect on viral detection rate in early infant samples. AIDS 2000; 14:1421-1428.
4. Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Jean-Phillip P, McIntyre J, and the CHER Study Team. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study [abstract #WESS 103]. 4th IAS Conference, Sydney, Australia, 22-25 July.
5. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 2006; 41:505-508.
6. Blanche S, Tardieu M, Duliege A, Rouzioux C, Le Diest F, Fukunaga K, et al. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child 1990; 144:1210-1215.
7. Bobat R, Moodley D, Coutsoudis A, Coovadia H, Gouws E. The early natural history of vertically transmitted HIV-1 infection in African children from Durban, South Africa. Ann Trop Paediatr 1998; 18:187-196.
8. Mbori-Ngacha D, Nduati R, John G, Reilly M, Richardson B, Mwatha A, et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: a randomized clinical trial. JAMA 2001; 286:2413-2420.
9. European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 1994; 94:815-819.
10. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243.
11. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, Richardson BA, Otieno PA, Bosire R, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Ped Infect Dis J 2004; 23:536-544.
12. Spira R, Lepage P, Msellati P, Van Der Perre P, Leroy V, Simonon A, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics 1999; 104:e56.
13. Chilongozi D, Wang L, Brown L, Taha T, Valentine M, Emel L, et al., for the HIVNET 024 Study Team. 2008. Morbidity and mortality among a cohort of HIV-1 infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Ped Infect Dis J 2008; 27:808-814.
14. Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, Sinkala M, et al. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 2006; 20:1313-1321.
15. Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
16. Chasela C, Chen YQ, Fiscus S, Hoffman I, Young A, Valentine M, et al. Risk factors for late postnatal transmission of human immunodeficiency virus type 1. Ped Infect Dis J 2008; 27:251-256.
17. Brown E, Chen YQ. Multiple imputation of timing of mother-to-child- transmission of HIV [Working Paper #324]. UW Biostatistics Working Paper Series. http://www.bepress.com/uwbiostat/paper324/. [Accessed 25 February 2008].
18. Rubin DB. Multiple imputation after 18+ years. JAm Stat Assoc 1996; 91:473-489.
19. Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154-2166.
20. Moodley D, Moodley J, Coovadia H, Gray C, McIntyre J, Hofmyer J, et al., for the South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus yype 1. J Infect Dis 2003; 187:725-735.
21. The Petra study team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178-1186.
22. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362:1171-1177.
23. Taha TE, Kumwenda NI, Hoover DI, Fiscus SA, Kafulafula G, Nkhoma C, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292:202-209.
24. Read J, and the Committee on Pediatric AIDS. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics 2007; 120:e1547-e1562.
25. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 2006; 6:726-732.
26. Sherman GG, Jones SA. Oral fluid human Immunodeficiency virus tests: improved access to diagnosis for infants in poorly resourced prevention of mother to child transmission programs. Ped Infect Dis J 2005; 24:253-256.